Peptide · Fact sheet
GHRP-2
Also known as growth hormone-releasing peptide-2 · pralmorelin
GHRP-2 is an experimental growth-hormone secretagogue that activates the ghrelin receptor. It is not FDA approved, and small human physiology studies do not prove that it builds muscle, improves recovery, or slows aging.
What is GHRP-2?
GHRP-2 is a synthetic six-amino-acid peptide that activates the growth-hormone secretagogue receptor, also called the ghrelin receptor.
It can increase growth-hormone release and appetite, but a hormone spike is a biomarker—not a demonstrated body-composition or performance outcome.
Benefits & claims
It is promoted online for muscle growth, recovery, fat loss, sleep, and anti-aging, sometimes alongside other growth-hormone-pathway peptides.
Human studies more clearly show appetite and hormone effects than the desired performance outcomes used in marketing.
What the evidence supports
- Small controlled studies show increased growth hormone and short-term food intake.
- Those biological effects do not demonstrate improved muscle mass, strength, recovery, or healthspan.
Research areas
- Growth-hormone release
- Appetite and food intake
- Endocrine testing and physiology
- Critical-illness metabolism in older research
- Growth-hormone and ghrelin-receptor physiology
- Appetite and metabolic research
Dosage & frequency
Human study contextGHRP-2 has human hormone-response research, but there is no established FDA-approved muscle, recovery, or anti-aging regimen.
Acute appetite and GH-response crossover experiment
Seven lean healthy men
- Amount
- 1 mcg/kg/hour
- Frequency
- One 270-minute experimental infusion
- Route studied or labeled
- Subcutaneous infusion
Acute food-intake and hormone measurements; not an approved repeated-use regimen.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Diagnostic or experimental endocrine responses do not establish long-term treatment benefit.
Interactions & precautions
- Human hormone-response studies do not establish a safe interaction profile with other GH or endocrine treatments.
What is still unresolved
- The clinical value and long-term metabolic risks of repeated use remain uncertain.
Side effects & risks
- FDA identifies potential immune reactions, aggregation, peptide impurities, and complexity from an unnatural amino acid.
- FDA notes reports of increased insulin requirements, infection, pancreatitis, and deaths in critically ill study participants, while stating that causality was not established.
- The peptide can increase appetite and may affect glucose and endocrine signaling in ways that conflict with popular body-composition claims.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Early human evidenceSmall controlled human studies establish short-term effects on growth hormone and food intake. They do not establish meaningful muscle growth, recovery, fat loss, sleep, or longevity benefits.
Studies
Small controlled physiology study of growth hormone and short-term food intake.
Small double-blind study showing exposure-related food-intake and hormone effects, not muscle benefit.
Controlled hormone-secretion study in young men; it did not test performance outcomes.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 5 sourced accounts by reported effect.
Appetite: reported experiences
More refreshing sleep and slight hunger
A commenter in the same discussion described easier sleep, waking refreshed, slightly greater appetite and modestly better workout recovery during about two months of nasal GHRP-2 exposure.
Reported use in this account
- Product
- Product described as GHRP-2
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Intranasal
- Duration
- About two months
The formulation was unverified and there were no sleep or recovery measurements. This cannot be transferred to other routes or products.
Read the original accountSleep benefit varied; hunger sometimes disrupted it
A different commenter described inconsistent sleep improvement across several growth-hormone secretagogues, with GHRP-2 and GHRP-6 sometimes worsening sleep through hunger.
Amount, frequency, route and duration could not be confirmed for this account.
This is a retrospective comparison of multiple unverified exposures, without separate records for each compound.
Read the original accountSweating and weakness after a combined first exposure
An author reported sweating, weakness and feeling unwell minutes after a first GHRP-2 and modified GRF exposure, followed later by hunger.
Reported use in this account
- Product
- Product described as GHRP-2
- Amount
- 100 mcg
- Frequency
- One reported administration
- Route
- Not specified clearly
- Duration
- One reported administration
Other exposures described: Modified GRF (1-29), reported at 100 mcg in the same event; Testosterone cypionate; hCG; Anastrozole; Cabergoline; Tadalafil
The same author identified a ketogenic diet and several other exposures in a later post. No glucose result or administration route was stated; the account does not establish hypoglycemia or isolate GHRP-2 as the cause.
Read the combined-exposure accountWeight: reported experiences
Perceived recovery benefits with earlier palpitations and pressure
A forum author described perceived sleep, recovery, strength and body-fat changes after about a month. They also described palpitations during an earlier GHRP-2 exposure and head pressure when CJC without DAC was involved.
Reported use in this account
- Product
- Product described as GHRP-2
- Amount
- 125–150 mcg, the individual's stated range
- Frequency
- Twice daily
- Route
- Not specified clearly
- Duration
- About one month
Other exposures described: Testosterone during the later exposure; CJC without DAC was tried and stopped
No outcomes or product contents were verified, and concurrent testosterone limits attribution. The palpitations came from an earlier exposure; the author later expressed a negative overall opinion without documenting a clinical assessment.
Read the month-long forum accountEnergy: reported experiences
Sweating and weakness after a combined first exposure
An author reported sweating, weakness and feeling unwell minutes after a first GHRP-2 and modified GRF exposure, followed later by hunger.
Reported use in this account
- Product
- Product described as GHRP-2
- Amount
- 100 mcg
- Frequency
- One reported administration
- Route
- Not specified clearly
- Duration
- One reported administration
Other exposures described: Modified GRF (1-29), reported at 100 mcg in the same event; Testosterone cypionate; hCG; Anastrozole; Cabergoline; Tadalafil
The same author identified a ketogenic diet and several other exposures in a later post. No glucose result or administration route was stated; the account does not establish hypoglycemia or isolate GHRP-2 as the cause.
Read the combined-exposure accountSleep: reported experiences
Very little sleep during combined exposure
An author described a week of poor sleep while using GHRP-2 with modified GRF, despite not feeling especially tired.
Reported use in this account
- Product
- Products described as GHRP-2 and modified GRF
- Amount
- Not specified clearly
- Frequency
- Roughly twice daily
- Route
- Not specified clearly
- Duration
- One week
Other exposures described: Modified GRF; stated numbers omit units
The paired products and existing sleep problems prevent isolating GHRP-2. The author's amount numbers omit units, so no amount is resolved; neither hormonal changes nor product identity were verified.
Read the original accountMore refreshing sleep and slight hunger
A commenter in the same discussion described easier sleep, waking refreshed, slightly greater appetite and modestly better workout recovery during about two months of nasal GHRP-2 exposure.
Reported use in this account
- Product
- Product described as GHRP-2
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Intranasal
- Duration
- About two months
The formulation was unverified and there were no sleep or recovery measurements. This cannot be transferred to other routes or products.
Read the original accountSleep benefit varied; hunger sometimes disrupted it
A different commenter described inconsistent sleep improvement across several growth-hormone secretagogues, with GHRP-2 and GHRP-6 sometimes worsening sleep through hunger.
Amount, frequency, route and duration could not be confirmed for this account.
This is a retrospective comparison of multiple unverified exposures, without separate records for each compound.
Read the original accountPerceived recovery benefits with earlier palpitations and pressure
A forum author described perceived sleep, recovery, strength and body-fat changes after about a month. They also described palpitations during an earlier GHRP-2 exposure and head pressure when CJC without DAC was involved.
Reported use in this account
- Product
- Product described as GHRP-2
- Amount
- 125–150 mcg, the individual's stated range
- Frequency
- Twice daily
- Route
- Not specified clearly
- Duration
- About one month
Other exposures described: Testosterone during the later exposure; CJC without DAC was tried and stopped
No outcomes or product contents were verified, and concurrent testosterone limits attribution. The palpitations came from an earlier exposure; the author later expressed a negative overall opinion without documenting a clinical assessment.
Read the month-long forum accountStrength: reported experiences
More refreshing sleep and slight hunger
A commenter in the same discussion described easier sleep, waking refreshed, slightly greater appetite and modestly better workout recovery during about two months of nasal GHRP-2 exposure.
Reported use in this account
- Product
- Product described as GHRP-2
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Intranasal
- Duration
- About two months
The formulation was unverified and there were no sleep or recovery measurements. This cannot be transferred to other routes or products.
Read the original accountPerceived recovery benefits with earlier palpitations and pressure
A forum author described perceived sleep, recovery, strength and body-fat changes after about a month. They also described palpitations during an earlier GHRP-2 exposure and head pressure when CJC without DAC was involved.
Reported use in this account
- Product
- Product described as GHRP-2
- Amount
- 125–150 mcg, the individual's stated range
- Frequency
- Twice daily
- Route
- Not specified clearly
- Duration
- About one month
Other exposures described: Testosterone during the later exposure; CJC without DAC was tried and stopped
No outcomes or product contents were verified, and concurrent testosterone limits attribution. The palpitations came from an earlier exposure; the author later expressed a negative overall opinion without documenting a clinical assessment.
Read the month-long forum accountHeadache: reported experiences
Perceived recovery benefits with earlier palpitations and pressure
A forum author described perceived sleep, recovery, strength and body-fat changes after about a month. They also described palpitations during an earlier GHRP-2 exposure and head pressure when CJC without DAC was involved.
Reported use in this account
- Product
- Product described as GHRP-2
- Amount
- 125–150 mcg, the individual's stated range
- Frequency
- Twice daily
- Route
- Not specified clearly
- Duration
- About one month
Other exposures described: Testosterone during the later exposure; CJC without DAC was tried and stopped
No outcomes or product contents were verified, and concurrent testosterone limits attribution. The palpitations came from an earlier exposure; the author later expressed a negative overall opinion without documenting a clinical assessment.
Read the month-long forum accountHeart symptoms: reported experiences
Perceived recovery benefits with earlier palpitations and pressure
A forum author described perceived sleep, recovery, strength and body-fat changes after about a month. They also described palpitations during an earlier GHRP-2 exposure and head pressure when CJC without DAC was involved.
Reported use in this account
- Product
- Product described as GHRP-2
- Amount
- 125–150 mcg, the individual's stated range
- Frequency
- Twice daily
- Route
- Not specified clearly
- Duration
- About one month
Other exposures described: Testosterone during the later exposure; CJC without DAC was tried and stopped
No outcomes or product contents were verified, and concurrent testosterone limits attribution. The palpitations came from an earlier exposure; the author later expressed a negative overall opinion without documenting a clinical assessment.
Read the month-long forum accountSensory changes: reported experiences
Sweating and weakness after a combined first exposure
An author reported sweating, weakness and feeling unwell minutes after a first GHRP-2 and modified GRF exposure, followed later by hunger.
Reported use in this account
- Product
- Product described as GHRP-2
- Amount
- 100 mcg
- Frequency
- One reported administration
- Route
- Not specified clearly
- Duration
- One reported administration
Other exposures described: Modified GRF (1-29), reported at 100 mcg in the same event; Testosterone cypionate; hCG; Anastrozole; Cabergoline; Tadalafil
The same author identified a ketogenic diet and several other exposures in a later post. No glucose result or administration route was stated; the account does not establish hypoglycemia or isolate GHRP-2 as the cause.
Read the combined-exposure accountApproval status
GHRP-2 is not FDA approved. FDA places GHRP-2 for injectable and nasal routes in a compounding category associated with potential significant safety risks.
No active FDA approval path identified
GHRP-2 has small human physiology studies, but no FDA-approved product and no cited active approval program for muscle, recovery, appetite, or aging uses.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Long-term human safety
- Whether any meaningful muscle, strength, recovery, sleep, or body-composition benefit exists
- Risks of combinations with other growth-hormone-pathway substances
- Product identity and quality outside an approved drug application
Summary
GHRP-2 changes hormone levels in small human studies. That does not establish better muscle growth or performance.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA: safety risks for selected compounded bulk substances
FDA's current substance-specific summary of evidence gaps and potential safety risks.
- pubmedGHRP-2 food-intake study in healthy men
Small controlled physiology study of growth hormone and short-term food intake.
- pubmedRandomized GHRP-2 appetite study
Small double-blind study showing exposure-related food-intake and hormone effects, not muscle benefit.
- pubmedRandomized GHRP-2 endocrine physiology study
Controlled hormone-secretion study in young men; it did not test performance outcomes.